In last trading session, Denali Therapeutics Inc (NASDAQ:DNLI) saw 0.87 million shares changing hands with its beta currently measuring 1.33. Company’s recent per share price level of $17.14 trading at $0.33 or 1.96% at ring of the bell on the day assigns it a market valuation of $2.44B. That closing price of DNLI’s stock is at a discount of -94.34% from its 52-week high price of $33.31 and is indicating a premium of 15.05% from its 52-week low price of $14.56. Taking a look at company’s average trading volume volume of 1.25 million if we extend that period to 3-months.
Denali Therapeutics Inc (NASDAQ:DNLI) trade information
Upright in the green during last session for gaining 1.96%, in the last five days DNLI remained trading in the green while hitting it’s week-highest on Friday, 05/03/24 when the stock touched $17.14 price level, adding 4.25% to its value on the day. Denali Therapeutics Inc’s shares saw a change of -20.13% in year-to-date performance and have moved 11.08% in past 5-day. Denali Therapeutics Inc (NASDAQ:DNLI) showed a performance of -9.74% in past 30-days.
Denali Therapeutics Inc (DNLI) estimates and forecasts
Statistics highlight that Denali Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -9.93% of value to its shares in past 6 months, showing an annual growth rate of -146.23% while that of industry is 12.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -80.10% from the last financial year’s standing.
13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 14.02M for the same. And 12 analysts are in estimates of company making revenue of 13.84M in the next quarter. Company posted 35.14M and 13.46M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -21.99% during past 5 years.
DNLI Dividends
Denali Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
